RecruitingPhase 3Drug trialStudy to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataThis study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.